SGTX

Sigilon Therapeutics, Inc. (SGTX) | Rumor.io

Sigilon Therapeutics

SGTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SGTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jul 3

Sigilon Therapeutics, Inc. (SGTX) has been upgraded by analyst Matthew Harrison from $7 to $21 with a rating of Equal-Weight.
The company's stock has seen significant price action, including a 122.2% increase on Thursday and a takeover bid by Eli Lilly.
The short-term setup for SGTX has a poor trend, with the price action indicating a bad short-term setup and a potential dump back to $3 if the deal does not go through.

Generated by AI

Sentiment

Of the messages about SGTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% 0
Bearish	0%	0%	0%	0% 0

Bullish· Jun 30

Sigilon Therapeutics, Inc. (SGTX) has seen a significant price increase, rising from $3.80 to $21.00 in just 5 days, with some investors reportedly buying out the entire float.
The company's potential acquisition by Eli Lilly (LLY) has contributed to its rapid growth, with some investors anticipating a premium price of up to $126.56 per share.
SGTX has already delivered substantial returns, with a 438% increase in 2023 and a 112% increase year-over-year, making it a promising investment opportunity for some investors.

Bearish· Jun 29

$SGTX has a history of significant price movements, including a 600% gap up, which may lead to increased volatility and a potential shorting opportunity.
The company's low float and post-split share structure make it vulnerable to short selling and potential price manipulation.
$SGTX is showing signs of weakness, including a loss of moving averages and trading below all averages, which may indicate a bearish trend.

Generated by AI

Topics

Of the messages about SGTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	100%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Analysts· Nov 30

Jefferies downgraded Sigilon Therapeutics to Hold from Buy, lowering the price target to $4.
Morgan Stanley maintained an Equal-Weight rating for Sigilon Therapeutics, lowering the price target from $9 to $4.5.
BTIG Research reiterated a Buy rating for Sigilon Therapeutics with a price target of $14.

Announcements· Jun 30

Sigilon Therapeutics, Inc. ($SGTX) stock soared 438.17% to $21.15 on Thursday after Eli Lilly ($LLY) announced a deal to purchase the company for up to $309.6B.
The deal, valued at up to $126.56 per share, is subject to certain benchmarks and could potentially boost Lilly's offer to $111 per share if all goes well.
Sigilon's CEO, Noubar Afeyan, a billionaire investor and co-founder of Moderna, is set to score a 3,000% gain on the tiny biotech company through his Flagship Pioneering VC funds.

Generated by AI

Community

Of the messages about SGTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	11.72%
Newcomers	0%	0%	0%	88.28%

Also Discussed

Investors talking about SGTX also mention

#	Name	Attention
1	Black Diamond Therapeutics, Inc.BDTX	0%new
2	EDTX - EdtechX Holdings Acquisition Corp. II	——
3	DICE - DICE Therapeutics, Inc.	——
4	XORTX Therapeutics Inc.XRTX	0%new
5	Minerva Surgical Inc.UTRS	0%0
6	Korro Bio Inc.KRRO	0%0
7	TRML - Tourmaline Bio, Inc.	——
8	AMAM - Ambrx Biopharma Inc.	——
9	AHI - Advanced Health Intelligence Ltd	——
10	Spyre Therapeutics, Inc.SYRE	0%new